"I am delighted to welcome Charlie as our Chief Medical Officer at this key stage of our clinical pipeline progress and expansion to oncology,” said Jesper Høiland, President and Chief Executive Officer of Radius. “Charlie brings over two decades of oncology drug development expertise, complementing our deep knowledge in osteoporosis, at a great time when we are moving forward with our pivotal elacestrant and abaloparatide patch studies. Charlie’s experience in steering the development of oncology drugs from late-stage trials into regulatory approvals, and his lead role in the worldwide development of Faslodex® (fulvestrant) in advanced metastatic breast cancer is invaluable to us as we near the anticipated start of our elacestrant Phase 3 study in the same indication. I look forward to working closely with Charlie to realize the full potential of our clinical assets and transform Radius as a key player in oncology and osteoporosis,” added Mr. Høiland.
“I am very excited to be joining Radius at this important time and lead the continued development of its strong pipeline,” said Dr. Morris. “After closely reviewing the efficacy and safety data supporting its promising and differentiated clinical profile, I believe elacestrant is uniquely positioned to potentially address unmet needs in the treatment of hormonal breast cancer. I have already had the chance to review and provide input to optimize elacestrant’s clinical development plan and look forward to initiating our Phase 3 study in the fourth quarter of this year. I am very excited by the potential to again provide a new treatment option that could improve outcomes for patients with breast cancer.”
Dr. Morris joins Radius from PsiOxus Therapeutics, a cancer gene therapy company, where he served as their Chief Development Officer. He is a graduate of
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. For more information, please visit www.radiuspharm.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations regarding our clinical trials, including the design and timing thereof; the progress in the development of our product candidates, including abaloparatide-patch and elacestrant (RAD1901); and the potential clinical uses and therapeutic and other benefits of our product candidates, including abaloparatide-patch and elacestrant.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we expect to need to raise additional funding, which may not be available; risks related to raising additional capital; our limited operating history; quarterly fluctuation in our financial results; our dependence on the success of TYMLOS, and our inability to ensure that TYMLOS will obtain regulatory approval outside the U.S. or be successfully commercialized in any market in which it is approved, including as a result of risk related to coverage, pricing and reimbursement; risks related to competitive products and any collaboration agreements failing to be successful; risks related to clinical trials, including our reliance on third parties to conduct key portions of our clinical trials and uncertainty that results will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates or during commercialization, if approved; risks related to manufacturing, supply and distribution; and the risk of litigation or other challenges regarding our intellectual property rights. These and other important risks and uncertainties discussed in our filings with the
Investor Relations Contact:
Source: Radius Health Inc.